[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

LT3518960T - Kontroliuojamo išsiskyrimo pth junginio dozavimo režimas - Google Patents

Kontroliuojamo išsiskyrimo pth junginio dozavimo režimas

Info

Publication number
LT3518960T
LT3518960T LTEPPCT/EP2017/074592T LT17074592T LT3518960T LT 3518960 T LT3518960 T LT 3518960T LT 17074592 T LT17074592 T LT 17074592T LT 3518960 T LT3518960 T LT 3518960T
Authority
LT
Lithuania
Prior art keywords
controlled
dosage regime
compound dosage
pth compound
release pth
Prior art date
Application number
LTEPPCT/EP2017/074592T
Other languages
English (en)
Inventor
Lars HOLTEN-ANDERSEN
Kennett Sprogøe
David Brian KARPF
Original Assignee
Ascendis Pharma Bone Diseases A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Bone Diseases A/S filed Critical Ascendis Pharma Bone Diseases A/S
Publication of LT3518960T publication Critical patent/LT3518960T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LTEPPCT/EP2017/074592T 2016-09-29 2017-09-28 Kontroliuojamo išsiskyrimo pth junginio dozavimo režimas LT3518960T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16191451 2016-09-29
EP17155843 2017-02-13
PCT/EP2017/074592 WO2018060310A1 (en) 2016-09-29 2017-09-28 Dosage regimen for a controlled-release pth compound

Publications (1)

Publication Number Publication Date
LT3518960T true LT3518960T (lt) 2023-09-11

Family

ID=60051488

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2017/074592T LT3518960T (lt) 2016-09-29 2017-09-28 Kontroliuojamo išsiskyrimo pth junginio dozavimo režimas

Country Status (24)

Country Link
US (5) US11590207B2 (lt)
EP (2) EP4275677A3 (lt)
JP (3) JP7197468B2 (lt)
KR (2) KR20240013849A (lt)
CN (2) CN109789189B (lt)
AU (2) AU2017336249B2 (lt)
BR (1) BR112019005533A2 (lt)
CA (1) CA3037442A1 (lt)
DK (1) DK3518960T5 (lt)
ES (1) ES2959995T3 (lt)
FI (1) FI3518960T3 (lt)
HR (1) HRP20231079T1 (lt)
HU (1) HUE063235T2 (lt)
IL (2) IL304086A (lt)
LT (1) LT3518960T (lt)
MX (1) MX2019003181A (lt)
NZ (1) NZ751969A (lt)
PL (1) PL3518960T3 (lt)
RS (1) RS64440B1 (lt)
SG (1) SG11201901576QA (lt)
SI (1) SI3518960T1 (lt)
SM (1) SMT202300305T1 (lt)
WO (1) WO2018060310A1 (lt)
ZA (1) ZA201901811B (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3391899T3 (da) * 2011-12-14 2020-08-24 Univ Arkansas Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein
EP4470613A2 (en) * 2016-03-01 2024-12-04 Ascendis Pharma Bone Diseases A/S Pth prodrugs
EP3518982B1 (en) * 2016-09-29 2024-11-27 Ascendis Pharma Bone Diseases A/S Controlled-release pth compounds
HRP20230383T1 (hr) 2016-09-29 2023-07-07 Ascendis Pharma Bone Diseases A/S Pth spojevi s malim omjerima maksimalne prema minimalnoj koncentraciji
EP4275677A3 (en) 2016-09-29 2024-01-10 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
US11624060B2 (en) 2017-02-10 2023-04-11 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
CA3099620A1 (en) * 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
US20220088149A1 (en) 2019-02-11 2022-03-24 Ascendis Pharma Bone Diseases A/S Liquid Pharmaceutical Formulations of PTH Conjugates
CN117586372A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效特立帕肽化合物

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744444A (en) 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US20050124537A1 (en) * 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050148763A1 (en) * 2002-02-01 2005-07-07 Chugai Seiyaku Kabushiki Kaisha Peg-binding pth or peg-binding pth derivative
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
WO2004089280A2 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
EP2932981B1 (en) 2003-09-19 2021-06-16 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
CN101151048A (zh) 2004-05-10 2008-03-26 纳斯泰克制药公司 增强甲状旁腺激素粘膜递送的组合物和方法
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
CN1597697A (zh) 2004-07-19 2005-03-23 中国药科大学 一种人的甲状旁腺素1－34肽相关肽－Pro－Pro－[Arg11]]hPTH(1－34)－Pro－Pro
US20060069021A1 (en) 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
JP2008511611A (ja) * 2004-08-30 2008-04-17 ルナメツド・インコーポレーテツド 治療用４−フェニル酪酸制御放出製剤
EP1736059A1 (en) 2005-06-21 2006-12-27 Fuji Oil Europe Structuring granular composition
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN1298386C (zh) 2005-08-31 2007-02-07 上海交通大学 甲状旁腺激素缓释微球的制备方法
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
CA2680690A1 (en) 2006-03-15 2007-09-20 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents to prevent or treat osteopenia
EP2063709A2 (en) 2006-09-15 2009-06-03 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
PL2084183T3 (pl) * 2006-10-13 2010-10-29 Lilly Co Eli Pegylowane pth jako modulatory receptora pth i ich zastosowania
US8101729B2 (en) * 2007-03-19 2012-01-24 Henry Joseph Niemczyk Pegylated amino acid derivatives and the process to synthesize the same
US8450273B2 (en) 2007-04-09 2013-05-28 The Board Of Trustees Of The University Of Arkansas Fusion proteins of collagen-binding domain and parathyroid hormone
JP5351889B2 (ja) 2007-06-21 2013-11-27 テクニシェ ユニバーシタット ミュンヘン インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
EP2175878A4 (en) 2007-07-11 2014-12-03 Belrose Pharma Inc POLYMER DRUG DISPENSING SYSTEM WITH A MULTIPLE SUBSTITUTED AROMATIC PART
US7633977B2 (en) 2007-08-08 2009-12-15 Wisconsin Alumni Research Foundation Multispectral laser with improved time division multiplexing
EP2052736A1 (en) 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
PT2237799T (pt) * 2008-02-01 2019-07-05 Ascendis Pharma As Pró-fármaco compreendendo um ligador autoclivável
LT2279007T (lt) 2008-04-29 2016-10-10 Ascendis Pharma Growth Disorders Division A/S Pegiliuoto rekombinantinio žmogaus augimo hormono junginiai
CA2723263A1 (en) 2008-05-23 2009-11-26 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
JP2012500284A (ja) 2008-08-19 2012-01-05 フェリング ベスローテン フェンノートシャップ ペプチド性ｐｔｈ受容体アゴニスト
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
CN102472593A (zh) 2009-07-16 2012-05-23 洛克希德马丁公司 用于换热器的螺旋状管束的配置
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
PE20121170A1 (es) 2009-07-31 2012-09-10 Sanofi Aventis Deutschland Composicion de insulina de accion prolongada
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
HUE052816T2 (hu) 2009-07-31 2021-05-28 Ascendis Pharma As Biológiailag lebontható polietilénglikol bázisú vízoldható hidrogélek
EP2459227B1 (en) 2009-07-31 2021-03-17 Ascendis Pharma A/S Prodrugs containing an aromatic amine connected by an amide bond to a carrier
CN102548583B (zh) 2009-07-31 2015-04-22 赛诺菲-安万特德国有限公司 包含胰岛素连接物缀合物的前药
AR078458A1 (es) 2009-09-30 2011-11-09 Sanofi Aventis Deutschland Conjunto de accionamiento, vastago de piston, dispositivo para la entrega de drogas, y uso de un resorte
EP2482881B1 (en) 2009-09-30 2013-10-23 Sanofi-Aventis Deutschland GmbH A mechanism for a drug delivery device
US20130053405A1 (en) * 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
CA2783296C (en) 2009-12-15 2019-01-15 Ascendis Pharma As Growth hormone composition
US20120289571A1 (en) 2009-12-31 2012-11-15 Enzon Pharmaceuticals, Inc. Polymeric conjugates of aromatic amine containing compounds including releasable urea linker
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
US20110229580A1 (en) * 2010-03-22 2011-09-22 Indian Institute of Technology Bombay, School of Biosciences and Bioengineering Compositions and methods for nano-in-micro particles
EP4450523A2 (en) 2010-04-02 2024-10-23 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
ES2584381T3 (es) 2010-05-05 2016-09-27 Prolynx Llc Liberación controlada de compuestos activos desde conjugados macromoleculares
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
MX358161B (es) * 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
SG185440A1 (en) 2010-05-21 2012-12-28 Xl Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
US8865220B2 (en) * 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
WO2012002047A1 (ja) 2010-06-30 2012-01-05 Ｎｅｃソフト株式会社 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム
US20120040320A1 (en) * 2010-08-13 2012-02-16 Nadeau Daniel A Injection Simulation Device and Methods Thereof
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
CA2843881C (en) * 2011-08-12 2020-05-26 Ascendis Pharma A/S Sustained release composition of prostacyclin
EP3643306A3 (en) * 2011-08-12 2020-08-26 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
EP2741778A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
AU2012296954B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
EP2741782B1 (en) 2011-08-12 2020-05-06 Ascendis Pharma A/S Protein carrier-linked prodrugs
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
JP2014528465A (ja) * 2011-10-12 2014-10-27 アセンディス ファーマ オフサルモロジー ディヴィジョン エー／エス 眼の状態の予防及び治療
DE102011116960B3 (de) 2011-10-26 2012-10-25 Stahlbrandschutz Gmbh Dämmschichtbildendes Anstrichmittel
DE102011117182A1 (de) 2011-10-28 2013-05-02 Ruhrpumpen Gmbh Teilstromführung, insbesondere einer Magnetkupplungspumpe
US8883862B2 (en) 2012-01-12 2014-11-11 Kaohsiung Medical University Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel
EP2841109A1 (en) 2012-04-25 2015-03-04 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US9457096B2 (en) * 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
US9718868B2 (en) 2012-08-28 2017-08-01 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods and making and using thereof
MX370543B (es) * 2012-10-11 2019-12-17 Ascendis Pharma Ophthalmology Div A/S Profarmacos neutralizantes del factor de crecimiento endotelial vascular para el tratamiento de afecciones oculares.
MX363462B (es) * 2012-10-11 2019-03-25 Ascendis Pharma As Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
CA2883833C (en) * 2012-10-11 2020-10-27 Ascendis Pharma A/S Hydrogel prodrugs
US20150250882A1 (en) 2012-10-17 2015-09-10 Novo Nordisk Health Care Ag Fatty Acid Acylated Amino Acids for Growth Hormone Delivery
WO2014086961A1 (en) * 2012-12-07 2014-06-12 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
GB201303771D0 (en) * 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
AU2014257745B2 (en) * 2013-04-22 2018-10-04 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing modified drugs
WO2015031709A1 (en) * 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations comprising a peptide and a vasodilatory agent
US10040850B2 (en) * 2013-10-08 2018-08-07 Ascendis Pharma A/S Protecting group comprising a purification tag
EP2868326A1 (en) * 2013-11-04 2015-05-06 Université Pierre et Marie Curie (Paris 6) Peptide inhibitors of TEAD/YAP-TAZ interaction
CA2955569C (en) 2014-08-06 2023-02-14 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016110577A1 (en) 2015-01-09 2016-07-14 Ascendis Pharma A/S Cnp prodrugs
AR105319A1 (es) * 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EP4470613A2 (en) 2016-03-01 2024-12-04 Ascendis Pharma Bone Diseases A/S Pth prodrugs
EP4275677A3 (en) 2016-09-29 2024-01-10 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
EP3518982B1 (en) 2016-09-29 2024-11-27 Ascendis Pharma Bone Diseases A/S Controlled-release pth compounds
HRP20230383T1 (hr) 2016-09-29 2023-07-07 Ascendis Pharma Bone Diseases A/S Pth spojevi s malim omjerima maksimalne prema minimalnoj koncentraciji
SG11201901534VA (en) 2016-09-29 2019-03-28 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
CA3099620A1 (en) 2018-05-18 2019-11-21 Ascendis Pharma Bone Diseases A/S Starting dose of pth conjugates
US20220088149A1 (en) 2019-02-11 2022-03-24 Ascendis Pharma Bone Diseases A/S Liquid Pharmaceutical Formulations of PTH Conjugates
BR112022010419A2 (pt) 2020-01-13 2022-08-23 Ascendis Pharma Bone Diseases As Tratamento de hipoparatireoidismo

Also Published As

Publication number Publication date
HUE063235T2 (hu) 2024-01-28
DK3518960T5 (da) 2024-09-02
US20230248836A1 (en) 2023-08-10
AU2017336249A1 (en) 2019-03-21
SG11201901576QA (en) 2019-03-28
CN109789189B (zh) 2024-01-23
HRP20231079T1 (hr) 2023-12-22
JP2023017796A (ja) 2023-02-07
IL304086A (en) 2023-08-01
KR102627405B1 (ko) 2024-01-18
CA3037442A1 (en) 2018-04-05
ZA201901811B (en) 2019-12-18
NZ751969A (en) 2023-04-28
EP4275677A3 (en) 2024-01-10
US20230381284A1 (en) 2023-11-30
RS64440B1 (sr) 2023-09-29
KR20240013849A (ko) 2024-01-30
IL265591B2 (en) 2023-12-01
US11590207B2 (en) 2023-02-28
EP3518960B1 (en) 2023-07-19
FI3518960T3 (fi) 2023-10-04
KR20190062496A (ko) 2019-06-05
US20200023041A1 (en) 2020-01-23
BR112019005533A2 (pt) 2019-06-18
EP3518960A1 (en) 2019-08-07
JP7197468B2 (ja) 2022-12-27
US11918628B2 (en) 2024-03-05
CN109789189A (zh) 2019-05-21
JP2019535648A (ja) 2019-12-12
SMT202300305T1 (it) 2023-11-13
RU2019112913A (ru) 2020-10-30
PL3518960T3 (pl) 2023-12-27
WO2018060310A1 (en) 2018-04-05
DK3518960T3 (da) 2023-09-04
IL265591A (en) 2019-05-30
EP4275677A2 (en) 2023-11-15
JP2024041859A (ja) 2024-03-27
US20230321198A1 (en) 2023-10-12
US11890326B2 (en) 2024-02-06
US20240245755A1 (en) 2024-07-25
JP7418527B2 (ja) 2024-01-19
ES2959995T3 (es) 2024-02-29
AU2017336249B2 (en) 2024-08-01
CN117838873A (zh) 2024-04-09
IL265591B1 (en) 2023-08-01
AU2024259658A1 (en) 2025-01-02
MX2019003181A (es) 2019-08-05
RU2019112913A3 (lt) 2021-01-18
SI3518960T1 (sl) 2023-11-30

Similar Documents

Publication Publication Date Title
SI3529248T1 (sl) Farmacevtske spojine
LT3518960T (lt) Kontroliuojamo išsiskyrimo pth junginio dozavimo režimas
LT3423103T (lt) Pth provaistai
EP3319606A4 (en) PHARMACEUTICAL COMPOUND
DK3265421T3 (da) Doseringssystem
DK3439667T3 (da) Cgas antagonist forbindelser
DK3310231T3 (da) Doseringsindretning
DK3298027T3 (da) Anthelmintiske depsipeptidforbindelser
DK3529240T3 (da) Farmaceutiske forbindelser
BR112017027227A2 (pt) Agente anti-câncer
LT3464336T (lt) Junginiai
MA42840A (fr) Composé pharmaceutique
EP3437644A4 (en) MEDICINE
LT3383385T (lt) Melflufeno dozavimo režimas vėžio atveju
LT3362444T (lt) Junginiai
DK3359555T3 (da) Doseringsplaner
EP3533799A4 (en) CONNECTION
DK3597189T3 (da) Krystallinske forbindelser
DK3347403T3 (da) Polyalkoxyfedtforbindelse
EP3527216A4 (en) Medicine
DK3374357T3 (da) Disubstituerede diaryloxybenzoheterodiazol-forbindelser
LT3331885T (lt) Junginiai
EP3395344A4 (en) MEDICINE
EP3298005C0 (en) ANTI-CANCER COMPOUNDS
DK3728220T3 (da) Farmaceutiske forbindelser